Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Another trial demonstrated a significant reduction in body weight with the use of semaglutide, with subjects losing up to 14.9% of their initial body weight over a period of 68 weeks
RYBELSUS (semaglutide) tablets (formulation R2) are available as: 1.5 mg: white to light yellow, round shaped debossed with 1.5 on one side and novo on the other side
Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
As is evidenced in the figure, treatment with the INK inhibitor formulation dramatically reduced the ABR threshold shift at various frequencies
Jiang T, Zhou Y, Zhu J, Chen Z, Sun P, Zhang Q, et al
